Cellectis

430 East 29th Street / New York, NY
8 rue de la Croix Jarry / 75013 Paris
2500 Sumner Boulevard / Raleigh, NC
United States

Show jobs for this employer

3 articles with Cellectis

  • Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS). Dear Shareholders, In the context of the Covid-19 pandemic and in accordance with Ordinance no. 2020-321 of March 25, 2020, the provisions of which were extended until July 31, 2021 by Decree no. 2021-255 of March 9, 2021, this general meeting will be held in closed session, i.e. without the physical presence of the shareholders and persons who are usually able to attend.

  • Cellectis S.A., a clinical-stage biotechnological company employing its core proprietary technologies to develop best-in-class products based on gene-edited allogeneic CAR T-cells in the field of immuno-oncology, announced that it has completed sales of approximately $47 million of American Depositary Shares pursuant to the Company’s ATM program established on March 29, 2021, through Jefferies LLC, acting as sales agent.

  • Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) (the “Company”), a clinical-stage biotechnological company employing its core proprietary technologies to develop best-in-class products based on gene-edited allogeneic CAR T-cells in the field of immuno-oncology, today announced that it has filed a prospectus supplement with the Securities and Exchange Commission (“SEC”) relating to an At-